The accuracy of the Montenegro skin test for leishmaniasis in PCR-negative patients

Ana Bárbara Sapienza Pinheiro[1], Patricia Shu Kurizky[2], Marina de Freitas Ferreira[3], Marco Antonio de Souza Mota[3], Jaqueline Santos Ribeiro[3], Edson Zuza de Oliveira Filho[2], Carlos Augusto Souza[2], Daniel Holanda Barroso[2], Raimunda Nonata Ribeiro Sampaio[2,4,5] and Ciro Martins Gomes[1,2,3,4]

[1]. Universidade de Brasília, Núcleo de Medicina Tropical, Brasília, DF, Brasil.
[2]. Universidade de Brasília, Faculdade de Medicina, Pós-graduação em Ciências Médicas, Brasília, DF, Brasil.
[3]. Universidade de Brasília, Faculdade de Medicina, Brasília, DF, Brasil.
[4]. Universidade de Brasília, Faculdade de Medicina, Laboratório de Dermatomicologia, Brasília, DF, Brasil.
[5]. Universidade de Brasília, Faculdade de Ciências da Saúde, Pós-graduação em Ciências da Saúde, Brasília, DF, Brasil.

Abstract

Introduction: As highly specific molecular biology-based techniques may not be sensitive enough for the diagnosis of American tegumentary leishmaniasis (ATL), clinicians frequently rely on immunological tests before treatment initiation. Hence, the correct combination of diagnostic tests is imperative for ATL diagnosis. We aimed to evaluate the accuracy of the Montenegro (Leishmanin) skin test (MST) in polymerase chain reaction (PCR)-negative patients to accurately detect ATL. Methods: Patients with a clinical picture compatible with ATL were divided into ATL (confirmed by lesion smear, culture indirect immunofluorescence, and/or histopathology) and no-ATL (diseases that can mimic leishmaniasis) groups. Conventional PCR for the minicircle kDNA of Leishmania was performed, and the MST was carried out for PCR-negative patients. Results: Ninety-nine patients were included in this study, including 79 diagnosed with ATL (6 with mucocutaneous leishmaniasis) and 20 without ATL (no-ATL group). The MST showed a high sensitivity of 90.0% (95% confidence interval [CI] = 69.90-97.21) in PCR-negative patients that was 10% higher than the sensitivity reported in PCR-positive population (79.66%; 95% CI = 67.73-87.96). Conclusions: One of the most important reasons for PCR negativity among patients with active ATL is the presence of a strong cellular immunological response, especially in chronic and mucocutaneous leishmaniasis. This reinforces the considerable utility of the tests that detect cellular responses against Leishmania antigens such as the MST in PCR-negative patients when the performance in screening situations is questionable.

Keywords: Leishmaniasis. Cutaneous. Mucocutaneous. Diagnosis.
regulations. In endemic areas, a positive MST result can also be attributed to previous leishmaniasis or an asymptomatic exposure to the parasite (infection)².

Huge investments have been recently made in molecular biology techniques, and polymerase chain reaction (PCR) is gaining popularity. Strategies such as forensic DNA extraction, use of primer pairs to amplify the kDNA minicircle of *Leishmania* spp., and variations such as real-time-based PCR have improved the diagnosis sensitivity; however, under practical conditions, these strategies exhibit a maximum sensitivity of 90%⁴. Thus, a considerable number of patients may still be treated without the direct detection of parasites during diagnosis.

ATL, in its localized form, is known to induce intense cellular responses and granuloma formation. This immunological reaction may lower the parasite load in the lesion and consequently reduce the sensitivity of parasitological tests and PCR but may be insufficient to cure the disease⁶. This is particularly a problem in South America where *Leishmania* (*Vianna*) *brazilensis* infection is endemic⁸. This species is associated with the mucocutaneous form of leishmaniasis and sometimes with long-lasting clinical presentations, which are also related to low parasite loads⁹. As MST is associated with a cellular immunological response, we believe that its use in PCR-negative patients may be a rational and cost-effective strategy for the diagnosis of ATL.

In the present study, we evaluated the accuracy of MST in PCR-negative patients and compared its association with other immunological response assessments (such as the presence of granuloma in histopathological examination) to reduce the need for therapeutic tests in ATL management.

**METHODS**

We performed a cross-sectional accuracy study. After protocol creation, patients with a clinical picture compatible with ATL who were evaluated at the Dermatology Division of the University Hospital of Brasilia (HUB) from January 2012 to December 2015 and underwent a PCR test for skin fragments were consecutively included.

**Composite reference standard (the presently defined gold standard for ATL case definition)**

ATL case was defined by positive parasite visualization in skin smears, cultures, or histopathological examination. In the absence of the abovementioned criteria, ATL positivity was defined in the form of a highly compatible inflammatory infiltrate in histopathological examination, positive indirect immunofluorescence with no evidence of other diseases using special stains or PCR for mycobacteria, and complete cure after pentavalent antimonial therapy. Although the histopathology of ATL can take various forms, the presence of granuloma and/or plasma cell infiltrates in samples without amastigote forms was considered as highly compatible with ATL.

The no-ATL group comprised patients without ATL but with diseases that have a clinical picture similar to that of ATL. In these patients, differential diagnosis was confirmed by the same exams used for case evaluation (e.g., vascular ulcers, cutaneous tuberculosis, subcutaneous mycosis, pyoderma gangrenosum, squamous cell carcinoma).

**Index tests (presently evaluated diagnostic tests)**

**Polymerase chain reaction**

PCR was performed for the amplification of a 120-bp sequence in the minicircle kDNA of *Leishmania* spp. using the primers 5'-(G/C)(G/C)(G/C)CC(A/C)CTAT(A/T)TTACACCCAAACCC-3' and 5'-GGGGAGGGGCGTTCTGCGAA-3' (Eurofins MWG Operon®, Huntsville, AL, USA)¹². The reactions were performed on a Mastercycler® Pro thermocycler (Eppendorf®, Hamburg, Germany) at a final volume of 25 μL comprising 1x PCR buffer, 0.2 mM of each dNTP, 1.5 mM of magnesium chloride (MgCl₂), 0.5 μM of each primer, 2.0 units of Taq DNA polymerase (Invitrogen, Foster City, USA), and 5 μL of DNA template. The amplification cycles included an initial denaturation step of 3 min and 30 s at 94°C, followed by 35 cycles at 93°C (30 s), 60°C (1 min), and 72°C (1 min), and a final extension at 72°C (10 min) and incubation at 4°C. All reactions included a negative and positive control with *L. braziliensis* culture lysates. In brief, 2 μL of the amplified product was mixed with 2 μL of a xylene-cyanol preparation (Vetcet®, Duque de Caxias, Rio de Janeiro, Brazil) and 1 μL (1:100) of GelRed™ (Biotium®, Hayward, CA, USA) and the mixture was loaded onto a 2% agarose gel immersed in 1× Tris base, acetic acid, and ethylenediaminetetraaetic acid (EDTA) buffer. A 100-bp marker was used (Invitrogen®, São Paulo, Brazil). Electrophoresis was performed in a Sub-Cell® GT Cell 170-4403 horizontal tank (BIO-RAD®, Hercules, CA, USA) for 90 min at 90 V and 400 mA. The gel was visualized on an EC3 Imaging System (UVP®, Upland, CA, USA).

The subgenus was identified by PCR restriction fragment length polymorphism (RFLP) using the enzymes HaeIII and Bsr1 (New England Biolabs®, Inc., Ipswich, MA, USA) after an overnight incubation at 37°C and 65°C, respectively. Fragments were then visualized using polyacrylamide gel electrophoresis¹². All negative samples were processed using endogen C18X primers for DNA extraction, as described elsewhere¹².

**Montenegro (Leishmanin) skin test**

MST was performed using an antigen provided by the Centre for Production and Research of Immunobiológicos - CPPI, Pirajuara, Paraná, Brazil. A total of 0.1 mL of the solution was intradermally injected on the anterior surface of the left forearm. The solution comprised fragments of *L. amazonensis* (WHO reference strain MHOM/BR/73/PH8). The cocktail included 40 μg/mL of protein nitrogen, 0.005 g/mL phenol, 0.0098 g/mL sodium chloride, and distilled water to make the volume to 1 mL. The test was considered positive upon the formation of a papule of a diameter equal to or greater than 5 mm after 48 h.

**Statistical analysis**

Categorical variables were compared using the chi-square test or its exact version. Numerical variables were compared using the Mann-Whitney U test. Test results were compared using the McNemar’s test or Cohen’s kappa coefficient. The percentage of positive results in patients with ATL was used to calculate sensitivity, and that of negative results in patients without ATL was used to calculate specificity. Accuracy was calculated as the sum
of the true-positive and true-negative results divided by the total number of patients tested. Missing values were ignored in unpaired tests. The programmes SPSS 20.0 (IBM Corporation, Armonk, NY, USA) and SAS 9.4 (SAS Institute, Inc., Cary, NC, USA) were used for statistical analysis. Statistical significance was defined at p < 0.05, and the confidence interval (CI) was set at 95%.

Ethics

All patients participating in the study were required to sign a written consent form. This project was approved by the Ethics Committee of the Faculty of Medicine – University of Brasília (UnB) under the protocol number 37190914.0.0000.5558.

RESULTS

Ninety-nine patients were included in this study, of which 79 were diagnosed with ATL (6 with mucocutaneous leishmaniasis) and 20 were allocated to the control group. The demographic characteristics, including sex, age, lesion site, lesion size, and disease time, were similar between the groups (Table 1). PCR-RFLP technique detected L. viannia infection in 55 patients and L. amazonensis infection in 4 patients. The no-ATL group comprised 8 patients with subcutaneous mycosis, 6 with vascular ulcers, 3 with pyoderma gangrenosum, 2 with squamous cell carcinomas, and 1 patient with cutaneous tuberculosis.

The comparison between the results of all performed exams (index tests and the composite reference standard) revealed the best accuracy for PCR, which showed 100% specificity (Table 2 and Table 3). The results of different tests, in general, showed slight agreement (Table 2). As expected, 22 patients with negative cultures, 41 negative for amastigote in histopathology, and 22 patients with negative smears were detected positive for ATL in PCR. On the other hand, only 2 patients with positive culture results, 4 positive for amastigote in histopathology, and 4 patients with positive smears were deemed ATL negative in PCR.

In all subjects, PCR showed a sensitivity and specificity of 74.68% (95% CI = 64.11-82.97) and 100% (95% CI = 83.89-100), respectively, and a diagnostic accuracy of 79.8% (95% CI = 70.85-86.52). On the other hand, the sensitivity, specificity, and accuracy of MST were 82.28% (95% CI = 72.42-89.14), 60% (95% CI = 38.66-78.12), and 77.78% (95% CI = 68.64-84.84), respectively (Table 2).

MST showed 90.0% sensitivity (95% CI = 69.90-97.21) in PCR-negative patients, and this value was 10% higher than the sensitivity value reported in PCR-positive population (79.66%; 95% CI = 67.73-87.96). The evaluation of the samples positive for MST along with highly suggestive histopathological results (positivity for both MST and histopathologic criteria) revealed a better accuracy of 82.5% (95% CI = 68.05-91.25) and an improved specificity of 80% (95% CI = 58.40-91.93). No significant difference was observed in the comparison between only MST and MST + suggestive histopathological exam in PCR-negative patients (p = 0.125).

As part of the presently defined inclusion criteria, all patients with ATL were daily treated with meglumine antimoniate at 20 mg Sb5+/kg, as recommended by the Brazilian Ministry of Health for cutaneous and mucocutaneous forms of ATL. Two patients with mucocutaneous ATL (both presented negative PCR results) and 3 patients with cutaneous ATL (1 presented negative PCR results) were subjected to a similar second course of treatment to ensure complete healing. No influence of PCR result on treatment outcome was detected (p = 0.113). Cure was defined as complete lesion healing after 3 months from the end of the specific treatment.

### TABLE 1: Demographic and basic disease characteristics of patients with American tegumentary leishmaniasis and controls.

|                     | ATL group (79 patients) | No-ATL group (20 patients) | p-value |
|---------------------|-------------------------|-----------------------------|---------|
| Gender              | n (%)                   | n (%)                       |         |
| Male                | 49 (62.0)               | 14 (70.0)                   | 0.688   |
| Female              | 30 (38.0)               | 6 (30.0)                    |         |
| Lesion site:        |                         |                             |         |
| Head                | 15 (19.0)               | 5 (25.0)                    | 0.066   |
| Trunk               | 6 (7.6)                 | 1 (5.0)                     |         |
| Superior limbs      | 12 (15.2)               | 8 (40.0)                    |         |
| Inferior limbs      | 38 (48.1)               | 6 (30.0)                    |         |
| Multiple            | 8 (10.1)                | 0 (0.0)                     |         |
| Age, mean (STD)     | 49.8 (15.27)            | 46.7 (16.84)                | 0.452   |
| Diameter (cm), mean (STD) | 3.2 (1.85)            | 3.3 (1.59)                  | 0.881   |
| Disease duration (months), median (IQR) | 8.78 (16.6)            | 10.88 (27.8)                | 0.763   |

ATL: American tegumentary leishmaniasis, STD: Standard deviation; IQR: Interquartile range.
DISCUSSION

Considerable investment has been made in molecular biology studies for the diagnosis of ATL, as justified by the enhanced sensitivity and high specificity of these techniques. However, even the most precise techniques do not exhibit complete sensitivity in the clinical setting. Thus, clinicians are required to use other classical immunological tests for the diagnosis of ATL. In the absence of a gold standard diagnostic test, it is important to study the association between the existing tests before the prescription of toxic drugs to patients.

We hypothesized that one of the main factors that explain the negative PCR result in patients with active ATL is the concomitance of a strong cellular immune response and granuloma formation. This characteristic is frequently reported in chronic cases of ATL as well as in mucocutaneous leishmaniasis but tends to occur in almost all untreated infections caused by *L. braziliensis*. This is why MST, a cellular response test, was considerably more sensitive in PCR-negative patients (90.0%; 95% CI = 69.90-97.21) than in PCR-positive patients (79.66%; 95% CI = 67.73-87.96). Although serial testing is generally carried out to improve specificity, the use of MST in PCR-negative patients may be beneficial to enhance diagnostic sensitivity, probably owing to biological factors.

This effect was also used to improve the diagnostic accuracy of a rational diagnostic test combination. In general, specificity continues to be limited to 60% (95% CI = 38.66-78.12), which may serve as a limitation when PCR result is negative for suspected leishmaniasis cases. To warrant better specificity, we incorporated a parallel criterion of including highly suggestive histopathological

### Table 2: Information on the diagnostic accuracy of the tests used as a composite reference standard.

| Test                                | Sensitivity - positive/ATL (95% CI) | Specificity - negative/no-ATL (95% CI) | Accuracy (95% CI) | Comparison with PCR Kappa (95% CI) | p-value* |
|-------------------------------------|------------------------------------|---------------------------------------|-------------------|-------------------------------------|----------|
| Smear                               | 50.63% - 40/79 (39.84-61.37)       | 100% - 0/20 (83.89-100)               | 60.61% (50.76-69.66) | 0.29 (0.15-0.43)                   | < 0.001  |
| Culture                             | 46.84% - 37/79 (36.34-57.73)       | 100% - 0/20 (83.89-100)               | 57.58% (47.74-66.85) | 0.26 (0.13-0.39)                   | < 0.001  |
| Indirect immunofluorescence         | 69.62% - 55/79 (58.77-78.66)       | 80% - 16/20 (58.40-91.93)             | 71.72% (62.16-79.65) | 0.36 (0.19-0.54)                   | 1        |
| Amastigotes in histopathology       | 27.85% - 22/79 (19.17-38.58)       | 100% - 0/20 (83.89-100)               | 42.42% (33.15-52.26) | 0.13 (0.03-0.23)                   | < 0.001  |
| Amastigotes, plasma cells, and/or granuloma in histopathology | 88.61% - 70/79 (79.75-93.89) | 50% - 10/20 (29.93-70.07)               | 80.81% (71.96-87.36) | 0.39 (0.19-0.59)                   | < 0.001  |

*ATL: American tegumentary leishmaniasis, PCR: Polymerase chain reaction, CI: Confidence interval. *McNemar's test.

### Table 3: Diagnostic accuracy of the Montenegro skin test in the entire population, PCR-negative patients, and those subjected to PCR along with a strongly suggestive histopathology.

| Test                                | Sensitivity - positive/ATL (95% CI) | Specificity - negative/no-ATL (95% CI) | Accuracy (95% CI) | Comparison with PCR Kappa (95% CI) | p-value* |
|-------------------------------------|------------------------------------|---------------------------------------|-------------------|-------------------------------------|----------|
| PCR in the total population         | 74.68% - 59/79 (64.11-82.97)       | 100% - 0/20 (83.89-100)               | 79.80% (70.85-86.52) |                                    |          |
| Montenegro skin test in total population | 82.28% - 65/79 (72.42-89.14)       | 60% - 12/20 (38.66-78.12)             | 77.78% (68.64-84.84) |                                    |          |
| Montenegro skin test in PCR (+) patients | 79.66% - 47/59 (67.73-87.96)       | 74.68% (64.11-82.97)                   | 75.0% (59.81-85.81) |                                    |          |
| Montenegro skin test in PCR (-) patients | 90.00% - 18/20 (69.90-97.21)       | 82.50% (68.05-91.25)                   |                   |                                    |          |

*ATL: American tegumentary leishmaniasis, PCR: Polymerase chain reaction, CI: confidence interval.
findings (amastigote forms, granuloma formation, and/or plasma cell infiltrates) in MST evaluation. As a consequence, the diagnostic specificity improved (80%; 95% CI = 58.40-91.93) for PCR-negative patients (Table 2). However, the sensitivity was slightly reduced to 85% (95% CI = 63.96-94.76).

Non-invasive sampling techniques (swabs and scrap samples) have been found to be more suitable than tissue biopsies for PCR-based ATL diagnosis. We recommend non-invasive PCR for the diagnosis of ATL in regions with the proper structure. Second, in PCR-negative patients with suggestive epidemiological and clinical presentations, the tests that detect immunological cellular responses associated or not associated with histopathology are useful to reduce the rate of false-negative tests.

The main limitation of the present study is that all tests (PCR, histopathology, and MST) were performed at the same time for blinding purposes. We made the abovementioned recommendations based on a series interpretations from MST result after PCR. However, we believe that the performance of MST only after confirming PCR negativity tends to reveal higher MST values once the disease duration is positively related to the cellular response. A maximum sensitivity of 75% for PCR and 90% for MST may seem insufficient for field diagnosis, but this result is in line with previous studies conducted in this geographical region. It is also important to remember that cross-sectional accuracy studies result in reduced sensitivity values as compared to other methodologies conducted in well-controlled environments.

We conclude that one of the most important reasons for PCR negativity in patients with active ATL is the presence of a strong cellular immunological response, especially in cases of chronic and mucocutaneous leishmaniasis. This observation reinforces the use of tests that better detect the cellular response against *Leishmania*, such as MST, in PCR-negative patients because their performance in screening situations is questionable owing to variable accuracy. The analysis of the rational association with other exams such as histopathology is also beneficial. Future studies on other techniques that detect cellular responses in ATL are warranted.

**AUTHORS’ CONTRIBUTION**

PSK: development of the study and confection and revision of the manuscript; ABSP, MFF, MASM, JSR, EZOF, CAS, and DHB: development and execution of the study, revision of the manuscript; RNRS: development of the study and confection of the manuscript; CMG: development and execution of the study, confection and revision of the manuscript.

**CONFLICT OF INTEREST**

The authors declare that there is no conflict of interest.

**REFERENCES**

1. Lima MIS, Arruda VO, Alves EVC, de Azevedo APS, Monteiro SG, Pereira SRP. Genotoxic effects of the antileishmanial drug Glucantime. Arch Toxicol. 2010;84(3):227–32.

2. Gomes CM, Paula NA de, Morais OO de, Soares KA, Roselino AM, Sampaio RNR. Complementary exams in the diagnosis of American tegumentary leishmaniasis. An Bras Dermatol. 2014;89(5):701–9.

3. Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Vigilância das Doenças Transmissíveis. Manual de diagnóstico da leishmaniose tegumentar [recurso eletrônico] / Ministério da Saúde, Secretaria de Vigilância em Saúde, Departamento de Vigilância das Doenças Transmissíveis. – Brasília : Ministério da Saúde, 2017. 189 p.

4. Antônio L, Schubach A, Marzochi KBF, Fagundes A. Comparison between in vivo measurement of the Montenegro skin test and paper recording. Int J Dermatol. 2012;51(5):618–9.

5. Silveira TGV, Alessi SMA, Bertolini DA, Teodoro U, Lonardoni M, Roberto A, et al. Observations on laboratory diagnosis and cutaneous leishmaniasis epidemiology in the State of Paraná, South of Brazil. Rev Soc Bras Med Trop. 1999;32(4):413–23.

6. Gomes CM, Mazin SC, Santos ERD, Cesetti MV, Bachtold GAB, Cordeiro JHF, et al. Accuracy of mucocutaneous leishmaniasis diagnosis using polymerase chain reaction: systematic literature review and meta-analysis. Mem Inst Oswaldo Cruz. 2015;110(2):157–65.

7. Gomes CM, Cesetti MV, de Paula NA, Vernal S, Gupta G, Sampaio RNR, et al. Field validation of SYBR® Green- and TaqMan®-based real-time PCR using biopsy and swab samples to diagnose American tegumentary leishmaniasis in a Leishmania (V) braziliensis-endemic area. J Clin Microbiol. 2016;55(2):526–34.

8. Sevilha-Santos L, Santos Júnior DOS ACM, Medeiros-Silva V, Bergmann JO, da Silva EF, Segato LF, et al. Accuracy of qPCR for quantifying Leishmania DNA in different skin layers of patients with American tegumentary leishmaniasis. Clin Microbiol Infect. 2019;25(2):242–7.

9. Gomes CM, Cesetti MV, Morais OO, Mendes MST, Roselino AM, Sampaio RNR. The influence of treatment on the development of leishmaniasis recidiva cutis: a 17-year case–control study in Midwestern Brazil. J Eur Acad Dermatol Venereol. 2015;29(1):109–14.

10. Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS ONE. 2012;7(5):e55671.

11. Brelaz-de-Castro MCA, de Almeida AF, de Oliveira V, Bergmann JO, da Costa LF, Pereira VRA. Cellular immune response evaluation of cutaneous leishmaniasis patients cells stimulated with Leishmania (Viannia) braziliensis antigenic fractions before and after clinical cure. Cell Immunol. 2012;279(2):180–6.

12. Gomes CM, de Paula NA, Cesetti MV, Roselino AM, Sampaio RNR. Mucocutaneous leishmaniasis: accuracy and molecular validation of noninvasive procedures in a L. (V) braziliensis-endemic area. Diagn Microbiol Infect Dis. 2014;79(4):413–8.

13. Daneshbod Y, Oryán A, Davarmanesh M, Shirian S, Negahban S, Areldavood A, et al. Clinical, histopathologic, and cytologic diagnosis of mucosal leishmaniasis and literature review. Arch Pathol Lab Med. 2011;135(4):478–82.

14. Suárez M, Valencia BM, Jara M, Alba M, Boggild AK, Dujardin JC, et al. Quantification of *Leishmania* (Viannia) kDNA in ulcers of cutaneous leishmaniasis reveals inter-site and inter-sampling variability in parasite load. PLoS Negl Trop Dis. 2015;9(7):e0003936.

15. Adams ER, Gomez MA, Brelaz-de Castro MCA, de Oliveira V, Desjeux P, Cano J, et al. Cutaneous leishmaniasis diagnosis: How the need for accurate and modern techniques is being addressed in low income areas. EBioMedicine. 2018;38:19-20.

16. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2 Group. QUADAS-2: a revised tool for the
quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155(8):529-36.

18. Cohen JF, Korevaar DA, Altman DG, Bruns DE, Gatsonis CA, Hooft L, et al. STARD 2015 guidelines for reporting diagnostic accuracy studies: explanation and elaboration. BMJ Open. 2016;6(11):e012799.

19. Knottnerus JA, Muris JW. Assessment of the accuracy of diagnostic tests: the cross-sectional study. J Clin Epidemiol. 2003;56(11):1118-28.

20. Gurung P, Gomes CM, Vernal S, Leeflang MMG. Diagnostic accuracy of tests for leprosy: a systematic review and meta-analysis. Clin Microbiol Infect. 2019;25(11):1315-27.